Industry Strength Score
24/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NYMOX PHARMACEUTICAL CORP (NYMX) Stock Price & Overview
NASDAQ:NYMX • BSP733981026
Current stock price
0.2 USD
-0.05 (-19.68%)
At close:
0.1767 USD
-0.02 (-11.65%)
After Hours:
The current stock price of NYMX is 0.2 USD. Today NYMX is down by -19.68%. In the past month the price decreased by -50.94%. In the past year, price decreased by -51.16%.
NYMX Key Statistics
52-Week Range0.1688 - 0.7427
Current NYMX stock price positioned within its 52-week range.
1-Month Range0.1688 - 0.417
Current NYMX stock price positioned within its 1-month range.
- Market Cap
- 18.103M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.03
- Dividend Yield
- N/A
NYMX Stock Performance
Today
-19.68%
1 Week
-28.98%
1 Month
-50.94%
3 Months
-43.80%
Longer-term
6 Months -50.73%
1 Year -51.16%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
NYMX Stock Chart
NYMX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to NYMX. When comparing the yearly performance of all stocks, NYMX is a bad performer in the overall market: 94.81% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
NYMX Earnings
Next Earnings DateAug 15, 2023
Last Earnings DateMay 12, 2023
PeriodQ1 / 2023
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
NYMX Forecast & Estimates
Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
NYMX Financial Highlights
Over the last trailing twelve months NYMX reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 82.42% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-2.88M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%74.09%
Sales Q2Q%N/A
EPS 1Y (TTM)82.42%
Revenue 1Y (TTM)N/A
NYMX Ownership
Ownership
Inst Owners0.05%
Shares90.52M
Float46.27M
Ins Owners29.39%
Short Float %N/A
Short RatioN/A
NYMX Industry Overview
NYMX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 18 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
11/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
71%
Outperformed 71% of sub-industries
3 Month Rank
36%
Outperformed 36% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 18
- New Highs
- 0%
- New Lows
- 11.1%
- Average ROE
- 3.7%
- Average Profit Margin
- 3.1%
- Average Operating Margin
- 1.6%
- Average P/E
- 63.0
- Average Fwd P/E
- 9.2
- Average Debt/Equity
- 0.1
NYMX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.75 | 349.666B | ||
| AMGN | AMGEN INC | 14.8 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.57 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.73 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.64 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.13 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.06 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.54 | 24.944B | ||
| INCY | INCYTE CORP | 10.85 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NYMX
Company Profile
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. The company is headquartered in Saint-Laurent, Quebec. The firm is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (prostate enlargement, BPH) and for low-grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company’s lead drug candidate for BPH FT has completed Phase III development in more than 70 clinical centers in the United States. FT has completed a phase II trial in the United States. The company has also developed the AlzheimAlert test. The firm operates in Canada, the United States and Switzerland.
Company Info
IPO: 1997-11-26
NYMOX PHARMACEUTICAL CORP
St. Laurent, 9900 Cavendish Blvd Suite 306
Saint-Laurent QUEBEC H4M 2V2 CA
CEO: Paul Averback
Employees: 3
Phone: 18009369669.0
NYMOX PHARMACEUTICAL CORP / NYMX FAQ
What does NYMOX PHARMACEUTICAL CORP do?
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. The company is headquartered in Saint-Laurent, Quebec. The firm is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (prostate enlargement, BPH) and for low-grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company’s lead drug candidate for BPH FT has completed Phase III development in more than 70 clinical centers in the United States. FT has completed a phase II trial in the United States. The company has also developed the AlzheimAlert test. The firm operates in Canada, the United States and Switzerland.
What is the current price of NYMX stock?
The current stock price of NYMX is 0.2 USD. The price decreased by -19.68% in the last trading session.
Does NYMOX PHARMACEUTICAL CORP pay dividends?
NYMX does not pay a dividend.
What is the ChartMill rating of NYMOX PHARMACEUTICAL CORP stock?
NYMX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists NYMX stock?
NYMX stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of NYMX stock?
NYMOX PHARMACEUTICAL CORP (NYMX) operates in the Health Care sector and the Biotechnology industry.